CN104232732A - Mapk信号整合激酶2在治疗动脉粥样硬化中的功能和应用 - Google Patents
Mapk信号整合激酶2在治疗动脉粥样硬化中的功能和应用 Download PDFInfo
- Publication number
- CN104232732A CN104232732A CN201410512348.9A CN201410512348A CN104232732A CN 104232732 A CN104232732 A CN 104232732A CN 201410512348 A CN201410512348 A CN 201410512348A CN 104232732 A CN104232732 A CN 104232732A
- Authority
- CN
- China
- Prior art keywords
- mnk2
- apoe
- atherosclerosis
- mouse
- function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410512348.9A CN104232732B (zh) | 2014-09-29 | 2014-09-29 | Mapk信号整合激酶2在治疗动脉粥样硬化中的功能和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410512348.9A CN104232732B (zh) | 2014-09-29 | 2014-09-29 | Mapk信号整合激酶2在治疗动脉粥样硬化中的功能和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104232732A true CN104232732A (zh) | 2014-12-24 |
CN104232732B CN104232732B (zh) | 2016-03-02 |
Family
ID=52221625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410512348.9A Active CN104232732B (zh) | 2014-09-29 | 2014-09-29 | Mapk信号整合激酶2在治疗动脉粥样硬化中的功能和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104232732B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107937445A (zh) * | 2017-07-25 | 2018-04-20 | 北京希诺谷生物科技有限公司 | 利用体细胞克隆技术制备基因敲除犬的方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1920026A (zh) * | 2005-08-24 | 2007-02-28 | 上海人类基因组研究中心 | 人hMnk2基因序列、其编码蛋白及制备方法 |
-
2014
- 2014-09-29 CN CN201410512348.9A patent/CN104232732B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1920026A (zh) * | 2005-08-24 | 2007-02-28 | 上海人类基因组研究中心 | 人hMnk2基因序列、其编码蛋白及制备方法 |
Non-Patent Citations (2)
Title |
---|
王平章 等: "Mnk2与CBC~(VHL)泛素连接酶E3复合物的相互作用", 《中国科学C辑》, vol. 35, no. 6, 31 December 2005 (2005-12-31), pages 537 - 544 * |
郭津 等: "动脉硬化大鼠心肌钙敏感受体表达增加通过激活MAPK通路诱导细胞凋亡", 《中国科技论文在线》, vol. 6, no. 3, 31 March 2011 (2011-03-31), pages 231 - 236 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107937445A (zh) * | 2017-07-25 | 2018-04-20 | 北京希诺谷生物科技有限公司 | 利用体细胞克隆技术制备基因敲除犬的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104232732B (zh) | 2016-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Myricetin attenuated LPS induced cardiac injury in vivo and in vitro | |
Dong et al. | Interleukin‐8: a critical chemokine in biliary atresia | |
Yu et al. | Dendrobium chrysotoxum Lindl. alleviates diabetic retinopathy by preventing retinal inflammation and tight junction protein decrease | |
Maraslioglu et al. | Chronic ethanol feeding modulates inflammatory mediators, activation of nuclear factor-κB, and responsiveness to endotoxin in murine Kupffer cells and circulating leukocytes | |
Park et al. | Blockage of sphingosine‐1‐phosphate receptor 2 attenuates allergic asthma in mice | |
CN106074468B (zh) | 肉桂醛在制备能够诱导vegf表达和分泌的诱导剂中的用途 | |
Sasidharan et al. | Ameliorative potential of Tamarindus indica on high fat diet induced nonalcoholic fatty liver disease in rats | |
JP5749651B2 (ja) | 多形核細胞の動員および/または遊走を減少させる化合物および方法 | |
CN108686211A (zh) | 一种治疗肝纤维化的药物和治疗方法 | |
Bo et al. | 3-Methyladenine alleviates experimental subretinal fibrosis by inhibiting macrophages and M2 polarization through the PI3K/Akt pathway | |
CN104232732B (zh) | Mapk信号整合激酶2在治疗动脉粥样硬化中的功能和应用 | |
CN104225597A (zh) | Mapk信号整合激酶1在治疗动脉粥样硬化中的功能和应用 | |
CN104225627B (zh) | 白细胞免疫球蛋白样受体亚家族b成员4在治疗动脉粥样硬化中的功能和应用 | |
CN103784973B (zh) | Irf9基因在动脉粥样硬化中的功能及应用 | |
CN103784975B (zh) | Irf7基因在动脉粥样硬化中的功能及其抑制剂的应用 | |
CN103784971B (zh) | Irf3基因在动脉粥样硬化中的功能及其抑制剂的应用 | |
Xia et al. | Resveratrol protects the retina from I/R injury by inhibiting RGCS apoptosis, glial activation and expression of inflammatory factors | |
CN104258419A (zh) | 干扰素调节因子1基因在治疗动脉粥样硬化中的应用 | |
CN104324389B (zh) | 血液剪切力应答蛋白1在治疗动脉粥样硬化中的功能和应用 | |
CN104383561A (zh) | 信号调节蛋白1在治疗动脉粥样硬化中的功能和应用 | |
CN104225598A (zh) | microRNA150在治疗动脉粥样硬化中的功能和应用 | |
CN103784945B (zh) | Irf3基因在支架及内膜剥脱术后再狭窄中的功能和应用 | |
CN104198697B (zh) | 离心力和剪应力应答基因1(recs1)在治疗血管损伤后再狭窄中的功能和应用 | |
CN104383560A (zh) | 干细胞抗原-1在治疗动脉粥样硬化中的功能和应用 | |
CN104258395A (zh) | 核苷酸合成酶cad在治疗动脉粥样硬化中的功能和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191126 Address after: 430040 No.1, floor 1, No.17, eleven village, Changqing Garden, Dongxihu District, Wuhan City, Hubei Province (18) Patentee after: Wuhan Dafeng Biotechnology Co., Ltd Address before: 430072 Hubei Province, Wuhan city Wuchang District of Wuhan University Luojiashan Patentee before: WuHan University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191218 Address after: 430014 3119, floor 3, building 9, Guanggu science and technology port, 18 huashiyuan North Road, Donghu New Technology Development Zone, Wuhan City, Hubei Province Patentee after: Wuhan linyijia Gene Technology Co., Ltd Address before: 430040 No.1, floor 1, No.17, eleven village, Changqing Garden, Dongxihu District, Wuhan City, Hubei Province (18) Patentee before: Wuhan Dafeng Biotechnology Co., Ltd |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 430076 room 002, 16 / F, building D2, phase III, software new town, No. 8, Huacheng Avenue, Wuhan East Lake New Technology Development Zone, Wuhan, Hubei Province Patentee after: Wuhan Huikang Gene Technology Co.,Ltd. Address before: Room 3119, 3 / F, building 9, Guanggu science and technology harbor, 18 huashiyuan North Road, Donghu New Technology Development Zone, Wuhan City, Hubei Province, 430014 Patentee before: Wuhan linyijia Gene Technology Co.,Ltd. |